Test of an experimental drug for severe viral lung infection (ARDS)
Part of Lungs & breathing clinical trials.
This study tests an experimental drug (STSA-1002) for people with severe breathing problems caused by a viral infection. It aims to see if the drug can help improve oxygen levels and reduce the need for a breathing machine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have a viral respiratory infection (like flu or COVID-19) confirmed by a lab test.
- You have a very low blood oxygen level (PaO2/FiO2 ≤ 200) even with oxygen therapy.
- Your breathing problems started within the last 12–14 days, depending on whether you need a breathing tube.
- You are not pregnant, breastfeeding, and agree to use birth control during the study and for 3 months after.
- You have not had a stroke, heart attack, or major organ failure recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing new treatments for people with ARDS, a serious lung condition. The goal is to find therapies that help patients breathe better and recover faster. If you or a loved one has ARDS, this study may offer access to experimental treatments.
This trial looks at how the immune system might cause severe breathing problems (ARDS). It may help doctors understand what happens in the lungs during this condition and find better ways to treat it.
This trial tests a gentler way of using the breathing machine, and may add a machine that acts like an artificial lung, to give your lungs time to heal from ARDS. This could help you recover if your lungs are very strained.
This trial tests if bevacizumab can help people with ARDS (a serious lung condition) breathe better. It is for patients with mild, moderate, or severe ARDS who are already in the hospital.
This trial tests a new medicine called YD0743 for people who have both sepsis (a serious infection) and ARDS (a severe lung injury from the infection). The goal is to see if the medicine helps improve breathing and survival.
This study tests a medicine called AK0529 for babies and toddlers hospitalized with RSV. It aims to see if the drug helps them recover faster and is safe for this age group.
Hear when a new Acute Respiratory Distress Syndrome (ARDS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.